Login / Signup

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.

Timo PurmonenKari PuolakkaDevarshi BhattacharyyaMinal JainJanne Martikainen
Published in: Cost effectiveness and resource allocation : C/E (2018)
Secukinumab is a cost-effective treatment for PsA patients from a Finnish payer's perspective.
Keyphrases
  • end stage renal disease
  • prostate cancer
  • newly diagnosed
  • chronic kidney disease
  • combination therapy
  • systemic lupus erythematosus
  • patient reported outcomes